Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 7/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669323 | 0.91 | CETP (0.50) | CETPGPBAR1SERPINE1LMNASMN1; SMN2 | |
| SCHEMBL1901842 | 0.88 | CETP (0.61) | CETP | |
| SCHEMBL5669045 | 0.88 | CETP (0.46) | CETPGPBAR1SERPINE1LMNASMN1; SMN2 | |
| SCHEMBL16279935 | 0.88 | GPBAR1 (0.41) | CETPGPBAR1SERPINE1LMNASMN1; SMN2 | |
| SCHEMBL5148391 | 0.88 | GPBAR1 (0.48) | CETPGPBAR1SERPINE1LMNASMN1; SMN2 | |
| SCHEMBL16279384 | 0.86 | CETP (0.51) | CETPGPBAR1SERPINE1 | |
| SCHEMBL5668926 | 0.86 | SERPINE1 (0.49) | CETPGPBAR1SERPINE1 | |
| SCHEMBL16280127 | 0.85 | GPBAR1 (0.41) | CETPGPBAR1SERPINE1LMNASMN1; SMN2 | |
| SCHEMBL5669577 | 0.82 | GPBAR1 (0.39) | CETPGPBAR1SERPINE1LMNASMN1; SMN2 | |
| SCHEMBL5671215 | 0.81 | CETP (0.50) | CETPGPBAR1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885GPBAR1 329/4885SERPINE1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.